Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.

Phaedon D ZavrasAditi ShastriMendel GoldfingerAmit K VermaYogen Saunthararajah

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

More than 40 years of clinical trial history indicates mechanism, pathway, and therapeutic index properties of HMAs that underpin their almost exclusive success and teaches lessons for selection and design of combinations aiming to build on this treatment foundation.

Keyphrases

clinical trial
phase ii
double blind
randomized controlled trial
phase iii
combination therapy
climate change
risk assessment